Trial Profile
A study of pegylated alfa interferon, sunitinib and Tarceva [erlotinib] in patients with metastatic renal cell carcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Peginterferon alfa (Primary) ; Sunitinib (Primary)
- Indications Carcinoma; Renal cancer
- Focus Therapeutic Use
- 24 Aug 2008 Actual patient number added (10) as reported by ClinicalTrials.gov.
- 24 Aug 2008 Planned end date added (1 Jul 2008) as reported by ClinicalTrials.gov.
- 24 Aug 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.